Publications on or relating to PROSTVAC (PSA-TRICOM).
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Cancer Immunol Res. 2014;2:133-141.
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapyJournal for ImmunoTherapy of Cancer 2014, 2:34
PROSTVAC, PSA-targeted poxvirus-based active immunotherapy: new evidence for mechanism of action.J Clin Oncol. 2014;32:5s (suppl); Abstr 3080.
PROSTVAC® targeted immunotherapy candidate for prostate cancerImmunotherapy. 2014;6(3):235-47.
PSA-Tricom, a pox-viral vaccine in prostate cancer (PCa), alters tumor growth rates within 80 days after initiation in non-metastatic prostate cancer.J Clin Oncol. 2013;31 (suppl 6): Abstract 57.
A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel.J Clin Oncol. 2013;31(suppl 6): Abstract 102.
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor Immunity.Cancer Res. 2013;73:2493-2504.
Aire-dependent thymic development of tumor-associated regulatory T cells.Science. 2013;339:1219-1224
Dramatic and prolonged PSA response after retreatment with a PSA vaccine.Clin Genitourin Cancer. 2013;11:362-364.
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.Urology. 2013;81:1297-1302.
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.Cancer Res. 2012;72:3439-3444.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.Lancet Oncol. 2012;13:501-508.
Immunotherapy with MVA-BN®-HER2 induces HER 2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.Cancer Immunol Immunother. 2012;61:19-29.
A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC).J Clin Oncol. 2011;29(suppl 7): Abstract 163.
Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Vaccine. 2011;29:6485-6497.
Immunotherapy for prostate cancer: recent advances, lessons learned and areas for further research.Clin Cancer Res. 2011;17:3884-3891.
Intraprostatic vaccine administration in patients with locally recurrent prostate cancer.J Clin Oncol. 2011;29(suppl 7): Abstract 141.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.Cancer Immunol Immunother. 2010;59:663-674.
Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.J Clin Oncol. 2010;28:1099-1105.
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.Clin Cancer Res. 2008;14:4241-4249.